# DIrect Oral Anticoagulation and Bioprothesis Aortic Valve

Study · id `cardio:ct-nct05687448` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05687448](<https://clinicaltrials.gov/study/NCT05687448>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05687448

Browse, organ or system: Heart; Brain  
Browse, condition area: Stroke; Valve and congenital heart disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 1500 participants.

## Technical summary

Registry record NCT05687448. Randomized; no masking; primary purpose treatment. Start 2025-09 (anticipated); primary completion 2025-09 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1500 participants (planned count; ClinicalTrials.gov record NCT05687448, source copy `cardio:ctgov-nct05687448-2025-06-12`, retrieved 2026-10-26)
- Planned start: 2025-09 (anticipated) (ClinicalTrials.gov record NCT05687448, source copy `cardio:ctgov-nct05687448-2025-06-12`, retrieved 2026-10-26)
- Primary completion: 2025-09 (anticipated) (ClinicalTrials.gov record NCT05687448, source copy `cardio:ctgov-nct05687448-2025-06-12`, retrieved 2026-10-26)
- Completion: 2029-03 (anticipated) (ClinicalTrials.gov record NCT05687448, source copy `cardio:ctgov-nct05687448-2025-06-12`, retrieved 2026-10-26)
- Countries: France (ClinicalTrials.gov record NCT05687448, source copy `cardio:ctgov-nct05687448-2025-06-12`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05687448-2025-06-12`, retrieved 2026-10-26)

## The registry's words

- Brief title: DIrect Oral Anticoagulation and Bioprothesis Aortic Valve
- Acronym: DIAMOND
- Condition: Aortic Valve Disease
- Intervention (Drug): Apixaban 5 MG Oral Tablet
- Intervention (Drug): Aspirin 75 to 100mg once a day
- Lead sponsor: Assistance Publique - Hôpitaux de Paris
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Assistance Publique - Hôpitaux de Paris (`cardio:org-assistance-publique-hopitaux-de-paris`)

## Provenance

Content hash: 2b7e11fe6d0c4891ca1d8481f41a17e8503ecee481c12a7303eccfa5c50d63cf
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
